Furthermore, the immunostimulatory properties of E. coli, together with adoptive transferred T cells, launched in situ tumor vaccinations through augmenting the tumor neoantigen presentation and maturation of intratumor dendritic cells and priming of circulating CD8 T cells for distal tumor control. The gene discussed is CD8A; the disease is neoplasm.